Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;54(1):17-24.
doi: 10.5946/ce.2021.019. Epub 2021 Jan 22.

The Efficacy and Safety of Endoscopic Sleeve Gastroplasty as an Alternative to Laparoscopic Sleeve Gastrectomy

Affiliations

The Efficacy and Safety of Endoscopic Sleeve Gastroplasty as an Alternative to Laparoscopic Sleeve Gastrectomy

Jin Young Yoon et al. Clin Endosc. 2021 Jan.

Abstract

Endoscopic sleeve gastroplasty (ESG) is a therapeutic endoscopic technique for reducing the size of the gastric reservoir in obese patients, using a full-thickness endoscopic suturing device. The effectiveness of ESG in weight loss is significantly greater than that of high-intensity diet and lifestyle therapy and lower than that of laparoscopic sleeve gastrectomy (LSG). The efficacy at 12 months after ESG in terms of percentage of total body weight loss and excess body weight loss was approximately 16% and 60%, respectively. The well-known predictive factors for increased weight loss by ESG are good compliance with regular monitoring and post-procedure care involving a multidisciplinary team approach. Although the underlying mechanism of weight loss induced by ESG is debatable, delayed gastric emptying and early satiation are some of the proposed mechanisms. The pooled rate of adverse events after ESG reported in several meta-analysis studies ranged from 1.5% to 2.3% and the incidence of new-onset gastroesophageal reflux disease after ESG was negligible, indicating that ESG has a superior safety profile to LSG. Moreover, ESG reduced the risk of obesity-related metabolic comorbidities, evidenced by the reduction in HbA1c level, systolic blood pressure, triglyceride level, and risk of hepatic steatosis and fibrosis; it even improved the quality of life. ESG could be considered safe and qualify as an alternative treatment to LSG.

Keywords: Efficacy; Endoscopic sleeve gastroplasty; Laparoscopic sleeve gastroplasty; Obesity; Safety.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no potential conflicts of interest.

Figures

Fig. 1.
Fig. 1.
(A) Laparoscopic sleeve gastrectomy. (B) Endoscopic sleeve gastroplasty (used with permission of Mayo Foundation for Medical Education and Research, all rights reserved).
Fig. 2.
Fig. 2.
Endoscopic sleeve gastroplasty performed using a full-thickness endoscopic suturing device (used with permission of Mayo Foundation for Medical Education and Research, all rights reserved)

References

    1. Rønningen R, Wammer ACP, Grabner NH, Valderhaug TG. Associations between lifetime adversity and obesity treatment in patients with morbid obesity. Obes Facts. 2019;12:1–13. - PMC - PubMed
    1. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934. - PMC - PubMed
    1. Ali M, El Chaar M, Ghiassi S, Rogers AM. American Society for Metabolic and Bariatric Surgery updated position statement on sleeve gastrectomy as a bariatric procedure. Surg Obes Relat Dis. 2017;13:1652–1657. - PubMed
    1. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149:275–287. - PMC - PubMed
    1. ASGE Bariatric Endoscopy Task Force. ASGE Technology Committee. Abu Dayyeh BK, et al. Endoscopic bariatric therapies. Gastrointest Endosc. 2015;81:1073–1086. - PubMed

LinkOut - more resources